Vornorexant Tablets (Vornorexant) are a new type of medication for insomnia treatment, and have shown significant potential in the field of sleep disorder management in recent years.
What Are the Indications of Vornorexant Tablets?
Main Indications
The indication of Vornorexant Tablets is clearly the treatment of insomnia.
As an orexin receptor antagonist, it regulates the sleep-wake cycle by specifically blocking OX1 and OX2 receptors.
This unique mechanism of action allows it to effectively shorten sleep onset time, improve sleep quality, while maintaining a relatively natural sleep structure.
Dosage Forms, Strengths and Characteristics of Vornorexant Tablets
Strength Composition
Vornorexant Tablets are available in three strengths: 2.5 mg, 5 mg, and 10 mg.
In terms of formulation composition, the added ingredients for the 2.5 mg and 5 mg strengths are consistent, including lactose monohydrate, microcrystalline cellulose, hydroxypropyl cellulose, sodium starch glycolate, and magnesium stearate.
The 10 mg strength additionally contains yellow iron trioxide as a colorant on the basis of the above ingredients.
Appearance Characteristics
2.5 mg tablets: White uncoated tablets, approximately 5.5 mm in diameter, 2.7 mm in thickness, weighing about 70 mg, with identification code "T1".
5 mg tablets: White tablets with a score line, approximately 7 mm in diameter, 3.3 mm in thickness, weighing about 140 mg, with identification code "T2".
10 mg tablets: Off-white uncoated tablets, approximately 7 mm in diameter, 3.3 mm in thickness, weighing about 140 mg, with identification code "T3".
Storage Conditions for Vornorexant Tablets
Storage Environment Requirements
The storage conditions for Vornorexant Tablets clearly require storage at room temperature.
This storage condition applies to all three strengths, providing clear guidance for the preservation of the medication.
The requirement for room temperature storage means no special refrigeration is needed, facilitating daily use and storage for patients, while also reducing medication stability issues caused by temperature fluctuations.
Expiration Date Regulation
The unified expiration period of this medication is 36 months.
Precautions
The medication is packaged in blister packs (PTP packs). When using, special attention must be paid to removing the tablets from the PTP blister before taking them; do not swallow the entire blister pack directly.
This practice is mainly to prevent the risk of accidental ingestion of the PTP blister, as the sharp edges of the PTP blister may scratch the esophageal mucosa and even cause serious complications such as mediastinitis.
Healthcare providers should clearly inform patients of the correct administration method when delivering the medication.
